155 related articles for article (PubMed ID: 31926638)
1. Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
Iihara H; Shimokawa M; Hayasaki Y; Fujita Y; Abe M; Takenaka M; Yamamoto S; Arai T; Sakurai M; Mori M; Nakamura K; Kado N; Murase S; Shimaoka R; Suzuki A; Morishige KI
Gynecol Oncol; 2020 Mar; 156(3):629-635. PubMed ID: 31926638
[TBL] [Abstract][Full Text] [Related]
2. Study protocol for an open-label, single-arm, multicentre phase II trial to evaluate the efficacy and safety of combined triplet therapy and olanzapine for prevention of carboplatin-induced nausea and vomiting in gynaecological cancer patients.
Iihara H; Shimokawa M; Abe M; Hayasaki Y; Fujita Y; Nagasawa Y; Sakurai M; Matsuoka R; Suzuki A; Morishige K
BMJ Open; 2019 Jan; 9(1):e024357. PubMed ID: 30782732
[TBL] [Abstract][Full Text] [Related]
3. Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.
Iihara H; Shimokawa M; Gomyo T; Fujita Y; Yoshida T; Funaguchi N; Minato K; Kaito D; Osawa T; Yamada M; Hirose C; Suzuki A; Ohno Y
BMJ Open; 2019 Jul; 9(7):e028056. PubMed ID: 31278102
[TBL] [Abstract][Full Text] [Related]
4. Low-Dose Olanzapine Plus Granisetron and Dexamethasone for Carboplatin-Induced Nausea and Vomiting in Patients with Thoracic Malignancies: A Prospective Multicenter Phase II Trial.
Sakai C; Shimokawa M; Iihara H; Fujita Y; Ikemura S; Hirose C; Kotake M; Funaguchi N; Gomyo T; Imai H; Hakamata J; Kaito D; Minato K; Arai T; Kawazoe H; Suzuki A; Ohno Y; Okura H
Oncologist; 2021 Jun; 26(6):e1066-e1072. PubMed ID: 33811782
[TBL] [Abstract][Full Text] [Related]
5. Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
Yamamoto S; Iihara H; Uozumi R; Kawazoe H; Tanaka K; Fujita Y; Abe M; Imai H; Karayama M; Hayasaki Y; Hirose C; Suda T; Nakamura K; Suzuki A; Ohno Y; Morishige KI; Inui N
BMC Cancer; 2022 Mar; 22(1):310. PubMed ID: 35321690
[TBL] [Abstract][Full Text] [Related]
6. Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial.
Iihara H; Iwai M; Morita R; Fujita Y; Ohgino K; Ishihara T; Hirose C; Suzuki Y; Masubuchi K; Kawazoe H; Kawae D; Aihara K; Endo S; Fukunaga K; Yamazaki M; Tamura T; Kitamura Y; Fukui S; Endo J; Suzuki A
Lung Cancer; 2024 Jun; 192():107801. PubMed ID: 38678830
[TBL] [Abstract][Full Text] [Related]
7. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Tanaka K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Kusagaya H; Matsuura S; Uto T; Hashimoto D; Matsui T; Asada K; Suda T
Cancer Chemother Pharmacol; 2019 Jul; 84(1):147-153. PubMed ID: 31087137
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and emesis in patients receiving carboplatin-based chemotherapy for gynecologic cancers: a phase II study by the West Japan Gynecologic Oncology Group (WJGOG 131).
Nishio S; Aihara S; Shimokawa M; Fujishita A; Taniguchi S; Hachisuga T; Yanazume S; Kobayashi H; Murakami F; Numa F; Kotera K; Okura N; Toki N; Yokoyama M; Ushijima K
J Gynecol Oncol; 2018 Sep; 29(5):e77. PubMed ID: 30022637
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Single-dose First-generation 5-HT
Kaito D; Iihara H; Funaguchi N; Endo J; Ito F; Yanase K; Toyoshi S; Sasaki Y; Hirose C; Arai N; Kitahora M; Ohno Y; Itoh Y; Minatoguchi S
Anticancer Res; 2017 Apr; 37(4):1965-1970. PubMed ID: 28373467
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy.
Markman MR; Peterson G; Kulp B; Markman M
Gynecol Oncol; 2002 Jun; 85(3):435-7. PubMed ID: 12051870
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Yahata H; Kobayashi H; Sonoda K; Shimokawa M; Ohgami T; Saito T; Ogawa S; Sakai K; Ichinoe A; Ueoka Y; Hasuo Y; Nishida M; Masuda S; Kato K
Int J Clin Oncol; 2016 Jun; 21(3):491-7. PubMed ID: 26662632
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of neurokinin-1 receptor antagonists in the prevention of chemotherapy-induced nausea and vomiting in patients receiving carboplatin-based chemotherapy: A systematic review and meta-analysis.
Di Maio M; Baratelli C; Bironzo P; Vignani F; Bria E; Sperti E; Marcato M; Roila F
Crit Rev Oncol Hematol; 2018 Apr; 124():21-28. PubMed ID: 29548482
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Antiemetic Effect of Aprepitant/granisetron and Palonosetron Combined with Dexamethasone in Gynecological Cancer Patients Treated with Paclitaxel and Carboplatin Combination Regimen.
Obayashi K; Nagamine A; Yashima H; Ohshima S; Uchiyama C; Takahashi E; Takahashi Y; Araki T; Yamamoto K
Pharmazie; 2022 May; 77(5):157-161. PubMed ID: 35655378
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: a prospective single-arm study.
Ito F; Furukawa N
Support Care Cancer; 2017 Jun; 25(6):1941-1945. PubMed ID: 28160077
[TBL] [Abstract][Full Text] [Related]
17. Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin.
Furukawa N; Kanayama S; Tanase Y; Ito F
Support Care Cancer; 2015 Nov; 23(11):3317-22. PubMed ID: 25947257
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the oral neurokinin-1 receptor antagonist aprepitant for nausea and vomiting induced by cisplatin and carboplatin in Japanese patients with gynecological cancer.
Ikeda M; Shida M; Hirasawa T; Muramatsu T; Mikami M
J Obstet Gynaecol Res; 2017 Oct; 43(10):1613-1620. PubMed ID: 28691209
[TBL] [Abstract][Full Text] [Related]
19. Low Dose Olanzapine in the Prevention and Treatment of Carboplatin Induced Nausea and Vomiting: A Prospective Clinical Randomized Controlled Trial.
An Y; Zhang Z; Gu M; Zhao J; Jiang C; Zhao L; Jiang Y; Li H; Liu G; Jin G; Li Q
Curr Pharm Des; 2023; 29(23):1867-1874. PubMed ID: 37539930
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with paclitaxel/carboplatin.
Choi CH; Kim MK; Park JY; Yoon A; Kim HJ; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS
Support Care Cancer; 2014 May; 22(5):1181-7. PubMed ID: 24337621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
